Stock 1530 3SBIO INC.
Add to a list

ETFs 3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 08:08:04 06/02/2026 GMT 		5-day change 1st Jan Change
22.94 HKD -0.78% Intraday chart for 3SBio Inc. -1.55% -5.13%
12-02 3SBio Seeks HK$3.12 Billion via Share Sale MT
12-02 3SBio to place 105.2 million shares RE

ETFs positioned on 3SBio Inc.

Name Varia. Jan 1. Weight AuM
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD ETF Goldman Sachs ActiveBeta Emerging Markets Equity UCITS ETF - Acc - USD
+8.92%0.1% 11 M€
LEVERAGE SHARES -3X SHORT CHINA ETP SECURITIES - USD ETF Leverage Shares -3x Short China ETP Securities - USD
0.00%0.08% 0 M€
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD ETF Day Hagan/Ned Davis Research Smart Sector International ETF - USD
+6.33%0.01% 32 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
+1.21%0.01% 33,076 M€
RAREVIEW SYSTEMATIC EQUITY ETF - USD ETF Rareview Systematic Equity ETF - USD
+3.53%0% 50 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF Acc - EUR
+1.33%0% 864 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF - Distributing - EUR
+1.27%0% 64 M€
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Distributing - EUR
+0.85%0% 87 M€
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Acc - EUR
+1.08%0% 661 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF Acc - EUR
+0.61%0% 186 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF - Distributing - EUR
+0.90%0% 34 M€
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS Emerging Market Equity MSCI-EM (Unhedged) ETF - JPY
+7.30%0% 20 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF Acc - EUR
+0.43%0% 85 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF - Distributing - EUR
+0.45%0% 14 M€

Company Profile

Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
6,268
Sector
Pharmaceuticals
Calendar
03-30 - Q4 2025 Earnings Release (Projected)
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.37CNY
Average target price
34.72CNY
Spread / Average Target
+70.42%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. ETFs 3SBio Inc.

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition